Thank you to our speakers, sponsors, and delegates who joined us in 2024 for the summit! If you are interested in the 2025 event, please get in touch at info@hansonwade.com
Welcome to the 2nd CRISPR-Based Therapy Analytical Development Summit!
As genome editing therapies become ever-complex, drug developers urgently need to innovate the analytical tools available to effectively characterize the critical quality attributes of their drug substances and drug products. We are also witnessing increased regulatory scrutiny, with the FDA closely studying off-target analysis conducted ahead of the approval of Casgevy, before finalizing guidance for the field in January.
To meet the growing analytical demands you face, the 2nd CRISPR-Based Therapy Analytical Development Summit returned to unite 50+ key figures across Analytical Development, CMC & QC domains, all with the common goal of developing more precise, accurate, and sensitive analytical assays.
Delegates & speakers joined us in 2024 to discuss the most recent analytical innovations across both traditional and disruptive CRISPR-based therapies, and in vivo and ex vivo delivery; with expert discussions covering the following core themes:
-
- Characterization of guides, nucleases, delivery modalities, and full drug products, with Editas Medicine, Beam Therapeutics & Nvelop Therapeutics
-
- Robust non-clinical and CMC assay development, including biodistribution studies, potency assays, and on-/off- target sequencing detection, nomination, and prediction, with Tome Biosciences, Verve Therapeutics & Vertex Pharmaceuticals
- Meeting regulatory expectations for analytical data to successfully support IND submissions, with NIST, Prime Medicine & Metagenomi
If you are working to develop, characterize, and validate more robust analytical tools to enable the progression of your early R&D work into a clinical therapy, this is the collaborative forum to equip you with the latest innovation, case studies, and actionable insights to boost your analytical panel and strategy. Returning in 2025, please register your interest to receive updates on the upcoming meeting.
“With a broad representation from industry, academia, and regulators, I look forward to attending this year’s CRISPR-Based Therapy Analytical Development Summit and exchange ideas with peer researchers and developers.”
- Zack Zhang, Director, Analytical Development at Beam Therapeutics
THE 2024 EXPERT SPEAKER FACULTY INCLUDED:
Yune Kunes
Vice President, Head of Analytical Development, Formulation & Early-Stage QC
Prime Medicine
“It’s a great opportunity to talk about the trials and tribulations (and occasional glory) of getting CRISPR therapies to patients!”
- Andrew Kernytsky, Principal Consultant at Next Gen Editing
2024 Partners:
Who Attended in 2023?
“The 2024 CRISPR-Based Therapy Analytical Development Summit is an exciting conference because it brings together industry and academic leaders that are breaking new ground in genome editing to drive community consensus on standards for non-clinical and CMC assay development.”
- Daniel O'Connell, Senior Director at Tome Biosciences